S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:AFMD - Affimed Stock Price, Forecast & News

$2.33
-0.09 (-3.72 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$2.26
Now: $2.33
$2.49
50-Day Range
$2.32
MA: $2.72
$3.02
52-Week Range
$2.18
Now: $2.33
$4.68
Volume897,829 shs
Average Volume657,590 shs
Market Capitalization$177.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
CUSIPN/A
Phone49-62-2167-4360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.03 million
Book Value$0.76 per share

Profitability

Net Income$-23,000,000.00

Miscellaneous

Employees8,406
Market Cap$177.64 million
Next Earnings Date3/25/2020 (Estimated)
OptionableOptionable

Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.


Affimed (NASDAQ:AFMD) Frequently Asked Questions

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed's earnings last quarter?

Affimed NV (NASDAQ:AFMD) issued its earnings results on Tuesday, November, 19th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. The biopharmaceutical company earned $2.34 million during the quarter, compared to analyst estimates of $6.77 million. Affimed had a negative net margin of 25.43% and a negative return on equity of 29.52%. View Affimed's Earnings History.

When is Affimed's next earnings date?

Affimed is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Affimed.

What price target have analysts set for AFMD?

3 brokerages have issued 1 year target prices for Affimed's shares. Their forecasts range from $4.17 to $10.00. On average, they expect Affimed's share price to reach $7.39 in the next year. This suggests a possible upside of 217.2% from the stock's current price. View Analyst Price Targets for Affimed.

What is the consensus analysts' recommendation for Affimed?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.

Has Affimed been receiving favorable news coverage?

News headlines about AFMD stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Affimed.

Who are some of Affimed's key competitors?

What other stocks do shareholders of Affimed own?

Who are Affimed's key executives?

Affimed's management team includes the folowing people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
  • Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
  • Prof. Melvyn Little, Founder & Consultant
  • Dr. Martin Treder, Chief Scientific Officer (Age 49)

Who are Affimed's major shareholders?

Affimed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.04%), Acadian Asset Management LLC (4.03%), Point72 Asset Management L.P. (2.23%), State Street Corp (1.46%), AQR Capital Management LLC (1.39%) and Geode Capital Management LLC (0.87%).

Which major investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management LLP, Russell Investments Group Ltd., Virtu Financial LLC and California Public Employees Retirement System.

Which major investors are buying Affimed stock?

AFMD stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Point72 Asset Management L.P., NEA Management Company LLC, Alpine Global Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Strs Ohio and Barclays PLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.33.

How big of a company is Affimed?

Affimed has a market capitalization of $177.64 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.View Additional Information About Affimed.

What is Affimed's official website?

The official website for Affimed is http://www.affimed.com/.

How can I contact Affimed?

Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2167-4360 or via email at [email protected]


MarketBeat Community Rating for Affimed (NASDAQ AFMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  381 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  655
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel